Shows
MorgenbesprechungDer Krebs-Experte: Blut im Stuhl = Zu Spät – Vermeide diese Fehler, Darmkrebs ist UNNÖTIG!In dieser Morgenbesprechnung unterhalte ich mich mit dem renommierten Onkologen Univ.-Prof. Dr. Christoph Zielinski über das Thema Darmkrebs – eine der häufigsten, aber auch am meisten unterschätzten Krebsarten. Dabei ist er sehr gut vermeidbar und verhinderbar !Wir sprechen über:🔴 Die ersten, oft übersehenen Warnzeichen🔴 Warum Blut im Stuhl ein spätes Symptom ist🔴 Welche Rolle Vorsorge spielt – und warum du nicht warten solltest🔴 Für wen ein erhöhtes Risiko besteht (Familie, Alter, Lebensstil)🔴 Die größte Fehleinschätzung bei der Darmspiegelung🔴 Neue Therapieansätze & was heute alles möglich ist🎧 Wenn du denkst, „das betrifft mich nicht“ – solltest du dir genau diese Fol...2025-04-1654 minMorgenbesprechungDer Krebs-Experte: Handystrahlung, Mikroplastik & Süßstoffe – Risiko oder Mythos?In dieser Episode spreche ich mit Universitätsprofessor Dr. Christoph Zielinski, einem der führenden Experten für Krebs in Österreich. Wir beantworten die drängenden Fragen:
Gibt es Warnsignale, die man selbst erkennen kann, bevor es zu spät ist?
Was kann jeder von uns im Alltag tun, um sein Krebsrisiko zu senken?
Und warum ist Prävention oft genauso wichtig wie die beste Therapie?
Welche Impfungen können tatsächlich vor Krebs schützen?
Wie wichtig sind regelmäßige Vorsorgeuntersuchungen, und wann sollte man damit anfangen?
Prof. Zielinski erklärt, wie moderne Medizin hilft, Krebs früh zu erkennen, u...2024-11-301h 16
Ars BoniArs Boni 477 AI in Scientific Medical Publications: Increase in Efficiency or Plagiarism 2.0? (Prof. Dr. Georg Dorffner)We are talking to Prof. Dr. Georg Dorffner (MedUni Wien). Dorffner's main research focus is on applying state-of-the-art methods from digital signal processing and pattern recognition to the development of diagnostic support in various clinical fields. He also has served as a member of the committee at MedUni Wien givin guidance on AI use in medicalk research and training.
We will discuss the relevance of AI in medical research and education and possible changes to the medical curriculum. A prior version of this talk was given at a conference on AI, medicine and law at Juridicum on January 12.
Links:2024-02-0859 minArs BoniArs Boni 476 AI in Clinical Decision Making (Prof. Dr. Harald Kittler)We talk to Prof. Dr. Harald Kittler (MedUni Vienna). Kittler is a dermatologist and teaches and researches in vivo skin imaging, artificial intelligence, machine learning, simulation and computational biology, among other things.
We talk about the influence of machine learning and AI in medicine, especially in dermatology.
Links:
https://www.meduniwien.ac.at/hp/n094-malignantdiseases/research-groupssupervisors/supervisors-h-k/kittler-harald/
https://www.cecog.org/ai-in-medicine-vision-reality-legal-aspects/2024-01-2956 minArs BoniArs Boni 449 AI in der Medizin: Vision, Realität und Recht (Univ.-Prof. Dr. Christoph C. Zielinski)Wir sprechen mit Univ.-Prof. Dr. Christoph Zielinski über Künstliche Intelligenz in der Medizin und ihre rechtlichen Implikationen. Zielinski ist (gemeinsam mit Nikolaus Forgó) verantwortlich für die Organisation einer Tagung, zum Thema, die am 12. Januar 2023 im Juridicum stattfinden wird.
Links:
https://www.cecog.org/ai-in-medicine-vision-reality-legal-aspects/
https://innere-med-1.meduniwien.ac.at/unsere-klinischen-abteilungen/infektionen-und-tropenmedizin/mitarbeiterinnen/christiane-thallinger/
https://www.ordination-zielinski.eu/
2023-10-3043 min
CECOG Academy PodcastsGenetic Consenting Training Programme - Module 11Group consenting model2023-09-1902 min
CECOG Academy PodcastsGenetic Consenting Training Programme - Module 1What is genetic consenting?2023-09-1904 min
CECOG Academy PodcastsGenetic Consenting Training Programme - Module 2Why is genetic consenting important?2023-09-1903 min
CECOG Academy PodcastsGenetic Consenting Training Programme - Module 3How is genetic consenting performed?2023-09-1907 min
CECOG Academy PodcastsGenetic Consenting Training Programme - Module 4What is mainstream genetic consenting?2023-09-1902 min
CECOG Academy PodcastsGenetic Consenting Training Programme - Module 5The importance of mainstream cpnsenting2023-09-1906 min
CECOG Academy PodcastsGenetic Consenting Training Programme - Module 6Knowledge of genetics required by healthcare professionals prior to mainstream consenting2023-09-1908 min
CECOG Academy PodcastsGenetic Consenting Training Programme - Module 7Practical approach to mainstream consenting2023-09-1912 min
CECOG Academy PodcastsGenetic Consenting Training Programme - Module 8mainstream BRCA genetics: Learnings from an oncogenetic pathway2023-09-1905 min
CECOG Academy PodcastsGenetic Consenting Training Programme - Module 9Alternative models for genetic consenting2023-09-1903 min
CECOG Academy PodcastsGenetic Consenting Training Programme - Module 10Telegenetics model2023-09-1902 min
CECOG Academy PodcastsGenetic Consenting Training Programme - Module 12eHealth model2023-09-1904 min
CECOG Academy PodcastsGenetic Consenting Training Programme - Module 13Future approaches to BRCA testing - investigations into app-based testing2023-09-1911 min
Ars BoniArs Boni 292: Die Medizin und ihre Feinde (Univ.-Prof. Dr. Christoph Zielinski)Wir sprechen mit Univ.-Prof. Dr. med. Christoph Zielinski. Er ist u.a. Professor an der Medizinischen Universität Wien, Facharzt für Innere Medizin - (Hämatologie und internistische Onkologie; Humangenetik), Gründungsdirektor des Vienna Cancer Center, Direktor der Central European Cooperative Oncology Group (www.cecog.org) und Herausgeber von ESMO Open – Cancer Horizons. Wir sprechen vor allem über das von ihm gemeinsam mit Dr. Herbert Lackner verfasste Buch "Die Medizin und ihre Feinde", in dem eine Geschichte wissenschaftsfeindlicher Bewegungen in der Medizin, insb. auch in der Corona-Zeit erzählt und ergründet wird.
Links:
https://w...2022-05-3045 min
CECOG Academy Podcasts5. CECOG - Fireside Chats - Zoom in for HER2+ space: Pharmacology & clinical (efficacy and safety) for trastuzumab deruxtecan Later lines of treatmentZoom in for HER2+ space: Pharmacology & clinical (efficacy and safety) for trastuzumab deruxtecan Later lines of treatmentHost: Doz. Dr. Christiane ThallingerUniv. Prof. Dr. Evandro De AzambujaInstitut Jules BordetBelgiumUniv. Prof. Dr. Christoph ZielinskiProfessor of Medical Oncology and Clinical ImmunologyMedical Director, Wiener Privatklinik and Central European Cancer CenterWien, AustriaPresident, Central European Cooperative Oncology Group (CECOG)Editor in Chief, "ESMO Open - Cancer Horizons", 2016-20212021-04-3027 minCECOG Academy Podcasts6. CECOG - Fireside Chats - Targeted treatment options to improve outcomes in EGFRm NSCLCTargeted treatment options to improve outcomes in EGFRm NSCLCHost: Doz. Dr. Christiane ThallingerUniv. Prof Dr. Martin FilipitsInstitute of Cancer ResearchDepartment of Medicine IMedical University of ViennaUniv. Prof. Dr Bojan ZaricInstitute for Pulmonary Diseases of VojvodinaFaculty of MedicineUniversity of Novi Sad, Serbia2021-04-3024 minCECOG Academy Podcasts3. CECOG - Fireside Chats - How new treatments are impacting the work of Multidisciplinary Teams (MTD) (incl guidelines discussion)How new treatments are impacting the work of Multidisciplinary Teams (MTD) (incl guidelines discussion)Host: Doz. Dr. Christiane ThallingerSpeakers:Dr. Mila PetrovaMHAT NadezhdaSofia, BulgariaUniv. Prof. Dr. Christoph ZielinskiProfessor of Medical Oncology and Clinical ImmunologyMedical Director, Wiener Privatklinik and Central European Cancer CenterWien, AustriaPresident, Central European Cooperative Oncology Group (CECOG)Editor in Chief, "ESMO Open - Cancer Horizons", 2016-20212021-04-3047 minCECOG Academy Podcasts4. CECOG - Fireside Chats - Clinical implementation of immuno-oncology therapy in unresectable stage III NSCLCClinical implementation of immuno-oncology therapy in unresectable stage III NSCLCHost: Doz. Dr. Christiane ThallingerUniv. Prof.Dr. Tanja CuferUniversity Clinic GolnikMedical Faculty LjubljanaSloveniaUniv. Prof. Dr. Rafal DziadziuskoDepartment of Oncology and RadiotherapyMedical University of Gdansk2021-04-3044 minCECOG Academy Podcasts2. CECOG - Fireside Chats - Changing the ES-SCLC Paradigm with Immuno-Oncology CombinationsChanging the ES-SCLC Paradigm with Immuno-Oncology CombinationsHost: Doz. Dr. Christiane ThallingerSpeakers:Univ. Prof. Dr. Marko JakopovicThoracic Oncology Unit Department for Respiratory DiseasesUniversity Hospital Centre Zagreb, CroatiaUniv Prof Dr. Wolfgang Köstler Department of Medicine I,Clinical Division of Oncology,Medical University of Vienna, Austria2021-03-0226 minCECOG Academy Podcasts1. CECOG - Fireside Chats - Patient needs in later lines of mBC (testing, efficacy of current treatment – what do we need)Patient needs in later lines of mBC (testing, efficacy of current treatment – what do we need)Host: Doz. Dr. Christiane ThallingerUniv. Prof. Dr. Rupert BartschDepartment of Medicine I,Clinical Division of Oncology,Medical University of Vienna, AustriaDr. Alexandru Eniu, MD, PhDHÔPITAL RIVIERA-CHABLAIS, VAUD-VALAIS,Spécialiste FMH en oncologie médicaleMédecin chef - Responsable Breast UnitSwitzerland2021-02-2526 minCECOG Academy PodcastsCECOG - "PANCREAS CANCER ACADEMY 2020 - Panel discussion: Advocates only"PANCREAS CANCER ACADEMY 2020 - Panel discussion: Advocates only2020-12-171h 26CECOG Academy PodcastsCECOG - "PANCREAS CANCER ACADEMY 2020"Panel discussion: How COVID-19 affects Pancreas Cancer Patients2020-11-2759 minCECOG Academy PodcastsCECOG - "TIGER & LEOPARD"CECOG Offers TIGER and LEOPARD Virtual Transborder Tumour Boards to Deliver Optimal Cancer Care and Precision Medicine.2020-11-1204 minCECOG Academy PodcastsCECOG - "The Cancer Dashboard for Central and Southeastern Europe"In this podcast, the president of CECGO, Prof. Christoph Zielinski, describes the problems and shortcomings of cancer care in Central and Southeastern Europe, as compared to the Western part of the contiinent and describes ways to overcome the deficits by reduction of systemic health inequalities and improvement of access to cancer care by focussing on prevention, screening, early diagnosis, and access to state of the art cancer diagnosis and treatment. The Dashboard which has been developed together with key opnion leaders including oncolocgists, patient advocates, representatives of policy making bodies and reimbursement agencies calls for very defined endpoints which...2020-09-1709 min
CECOG Academy PodcastsCECOG - "Who we are and what we do"CECOG - "Who we are and what we do" by CECOG President Christoph Zielinski2020-08-2706 min
Medizin - Open Access LMU - Teil 19/22Impact of the Specific Mutation in KRAS Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three TrialsPurpose: This study investigated the impact of specific mutations in codon 12 of the Kirsten-ras (KRAS) gene on treatment efficacy in patients with metastatic colorectal cancer (mCRC). Patients: Overall, 119 patients bearing a KRAS mutation in codon 12 were evaluated. All patients received cetuximab-based first-line chemotherapy within the Central European Cooperative Oncology Group (CECOG), AIO KRK-0104 or AIO KRK-0306 trials. Results: Patients with KRAS codon 12 mutant mCRC showed a broad range of outcome when treated with cetuximab-based first-line regimens. Patients with tumors bearing a KRAS p.G12D mutation showed a strong trend to a more favorable outcome compared to other mutations (overall...2012-01-0100 min